1 / 41

Highlights From the 2013 Gastrointestinal Cancers Symposium

Highlights From the 2013 Gastrointestinal Cancers Symposium. Highlights of the 2013 Genitourinary Cancers Meeting. Phase 3 Metastatic Pancreatic Adenocarcimona (MPACT) Trial. Pancreatic Cancer. Comparison of Phase 2/Phase 3 Data.

louis-durham
Download Presentation

Highlights From the 2013 Gastrointestinal Cancers Symposium

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Highlights From the 2013 Gastrointestinal Cancers Symposium

  2. Highlights of the 2013 Genitourinary Cancers Meeting

  3. Phase 3 Metastatic Pancreatic Adenocarcimona (MPACT) Trial

  4. Pancreatic Cancer

  5. Comparison of Phase 2/Phase 3 Data

  6. S-1 vs Gemcitabine as Adjuvant Therapy for Early Stage Pancreatic Cancer - JASPAC

  7. Locally Advanced Disease

  8. Colorectal Cancer

  9. TRIBE Trial: FOLFOXIRI + Bevacizamab vs FOLFIRI + Bevacizamab

  10. AVEX Trial: Phase 3 in Elderly Patients

  11. Colorectal Cancer (CRC) Subtypes

  12. Mesenchymal Epithelial Transition (MET) Overexpression

  13. Gastric Cancer

  14. Human Epidermal Growth Factor 2 (HER-2) Expression: Influence of Neoadjuvant Chemotherapy

  15. Mechanism of Action: Ramicirumab

  16. REGARD Trial: Ramucirumab vs Placebo

  17. COUGAR Study: Phase 3 Docetaxel as Standard of Care for Second-line Therapy

  18. Pancreatic Neuroendocrine Tumors (pNET)

  19. Does Location of the Small Bowel Carcinoid (SBC) Influence Survival?

  20. Factors Predicting the Risk of Nodal Involvement

  21. PROMID Study: Octreotide LAR vs Placebo

  22. Ocreotide Use From SEER-MedicareDatabase

  23. Hepatocellular Carcinoma

  24. Results: Progression-free Survival

  25. Inhibitors of Growth Factor Receptors

  26. Phase 1/2 of Golvatinib + Sorafenib

  27. Survival Impact of Sorafenib: SEER Analysis

  28. Gastrointestinal Stromal Tumors (GIST)

  29. Surgical Resection After Imatinib vs Imatinib Alone

  30. Phase 2: Better Efficacy With Longer-term Adjuvant Dosing With Imatinib

  31. Abbreviations

  32. References

  33. References (cont)

  34. References (cont)

  35. References (cont)

  36. References (cont)

  37. References (cont)

  38. References (cont)

  39. References (cont)

  40. References (cont)

  41. References (cont)

More Related